-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Amid a notable positive session for the major equity indices, Biogen (NASDAQ:BIIB) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging results for its final-phase test for lecanemab, an experimental therapeutic for Alzheimer's disease. Given the breakthrough, other biotech stocks related to the condition jumped, including trial partner Eisai (OTCMKTS:ESALY) and sector rival Eli Lilly (NYSE:LLY).
The lecanemab therapeutic produced positive top-line results in Alzheimer's patients suffering from mild cognitive impairment, per the Motley Fool. Specifically, it "met the primary endpoint of significantly reducing the clinical decline" of key cognitive and functional metrics. In addition, the experimental treatment met certain secondary endpoints, including statistically significant benefits on cognition. Lecanemab removes built-up plaque in the brain called beta amyloid.
Naturally, the disclosure bolstered biotech stocks tied to Alzheimer's treatment due to the subsegment representing a clinical minefield. As the Washington Post mentioned in April 2020, the race for an effective treatment has been riddled with failure. "More than 200 promising leads have fallen through just in the past decade."
For Biogen, the current news is particularly sweet because it previously forwarded an Alzheimer's treatment called Aduhelm. However, Investor's Business Daily noted that "the benefits on cognition were dubious with one successful and one failed Phase 3 test."
In contrast, Mizuho Securities analyst Salim Syed described the results for lecanemab as "rather clean." At 18 months, for instance, "patients who received lecanemab showed a 27% slower decline in cognition compared with placebo recipients."
Biotech Stocks Rise, But Prudence Remains Vital
Based on historical challenges associated with Alzheimer's research and Biogen's own frustrations, Wall Street granted biotech stocks a massive lift. At the time of writing, ESALY skyrocketed 63% on Wednesday while LLY gained 8% — a tremendous performance for a blue chip.
SVB Securities analyst Marc Goodman weighed in on the news, suggesting that lecanemab should be clinically meaningful for patients. In turn, it could boost biotech stocks associated with treating Alzheimer's. "We expect that these positive results will reinvigorate the Alzheimer's disease space and increase the focus of the investor community for the two near-term anti-amyloid beta (drugs)," he said in a note.
Nevertheless, investors need to be cautious about getting too heavily involved in the aforementioned biotech stocks. Dr. Howard Fillit, chief science officer for the Alzheimer's Drug Discovery Foundation, stated that the results provided encouragement. However, the breakthrough only represents a first step in treating the disease.
"Amyloid-clearing drugs will provide an incremental benefit at best and there is still a pressing need for the next generation of drugs focused on other targets based on our knowledge of the biology of aging," he said in an emailed statement to Investor's Business Daily. "We are optimistic about the future as many of these drugs are in development."
Still, with the benchmark S&P 500 index down about 8% in the trailing month, Wall Street needed some good news. Investors got it in the form of Alzheimer's-associated biotech stocks.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市场新闻,股票建议和交易提示
Amid a notable positive session for the major equity indices, Biogen (NASDAQ:BIIB) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging results for its final-phase test for lecanemab, an experimental therapeutic for Alzheimer's disease. Given the breakthrough, other biotech stocks related to the condition jumped, including trial partner Eisai (OTCMKTS:ESALY) and sector rival Eli Lilly (NYSE:LLY).
在主要股指出现明显乐观的交易时段中, Bioge 纳斯达克股票代码:BIIB)在周三下午早些时候的交易中大幅上涨了37%,这确实使派对拉开了序幕。Biogen透露了其对lecanemab(一种阿尔茨海默氏病的实验疗法)的最后阶段测试的结果非常令人鼓舞。鉴于这一突破,与该病相关的其他生物技术股也出现了上涨,包括试验合作伙伴 卫材 (OTCMKTS: ESALY)和行业竞争对手 Eli Lilly (纽约证券交易所:LLY)。
The lecanemab therapeutic produced positive top-line results in Alzheimer's patients suffering from mild cognitive impairment, per the Motley Fool. Specifically, it "met the primary endpoint of significantly reducing the clinical decline" of key cognitive and functional metrics. In addition, the experimental treatment met certain secondary endpoints, including statistically significant benefits on cognition. Lecanemab removes built-up plaque in the brain called beta amyloid.
据称,lecanemab疗法在患有轻度认知障碍的阿尔茨海默氏症患者中取得了积极的结果 Motley Fool。具体而言,它 “达到了显著减少关键认知和功能指标临床下降的主要终点”。此外,实验性治疗达到了某些次要终点,包括在认知方面具有统计学意义的益处。Lecanemab 可去除大脑中积聚的称为β淀粉样蛋白的斑块。
Naturally, the disclosure bolstered biotech stocks tied to Alzheimer's treatment due to the subsegment representing a clinical minefield. As the Washington Post mentioned in April 2020, the race for an effective treatment has been riddled with failure. "More than 200 promising leads have fallen through just in the past decade."
当然,这一披露提振了与阿尔茨海默氏症治疗相关的生物技术股,因为该细分市场代表了临床雷区。作为 《华盛顿邮报》 2020年4月提到,寻求有效治疗的竞赛充满了失败。“仅在过去十年中,就有200多条有希望的线索消失了。”
For Biogen, the current news is particularly sweet because it previously forwarded an Alzheimer's treatment called Aduhelm. However, Investor's Business Daily noted that "the benefits on cognition were dubious with one successful and one failed Phase 3 test."
对于Biogen来说,目前的消息特别甜蜜,因为它之前转发了一种名为Aduhelm的阿尔茨海默氏症治疗方法。但是, 《投资者商业日报》 指出,“一项成功的第三阶段测试失败了,对认知的益处值得怀疑。”
In contrast, Mizuho Securities analyst Salim Syed described the results for lecanemab as "rather clean." At 18 months, for instance, "patients who received lecanemab showed a 27% slower decline in cognition compared with placebo recipients."
相比之下,瑞穗证券分析师萨利姆·赛义德将lecanemab的业绩描述为 “相当干净”。例如,在18个月时,“与安慰剂接受者相比,接受lecanemab治疗的患者的认知能力下降速度慢了27%。”
Biotech Stocks Rise, But Prudence Remains Vital
生物技术股上涨,但谨慎仍然至关重要
Based on historical challenges associated with Alzheimer's research and Biogen's own frustrations, Wall Street granted biotech stocks a massive lift. At the time of writing, ESALY skyrocketed 63% on Wednesday while LLY gained 8% — a tremendous performance for a blue chip.
基于与阿尔茨海默氏症研究相关的历史挑战和Biogen自己的挫败感,华尔街大幅提振了生物技术股。在撰写本文时,ESALY在周三飙升了63%,而LLY上涨了8%,这对于蓝筹股来说是一个了不起的表现。
SVB Securities analyst Marc Goodman weighed in on the news, suggesting that lecanemab should be clinically meaningful for patients. In turn, it could boost biotech stocks associated with treating Alzheimer's. "We expect that these positive results will reinvigorate the Alzheimer's disease space and increase the focus of the investor community for the two near-term anti-amyloid beta (drugs)," he said in a note.
SVB Securities分析师马克·古德曼对这一消息进行了权衡,认为lecanemab应该对患者具有临床意义。反过来,它可能会提振与治疗阿尔茨海默氏症相关的生物技术股。他在一份报告中说:“我们预计,这些积极的结果将重振阿尔茨海默氏病领域,并增加投资者界对两种短期抗β淀粉样蛋白(药物)的关注。”
Nevertheless, investors need to be cautious about getting too heavily involved in the aforementioned biotech stocks. Dr. Howard Fillit, chief science officer for the Alzheimer's Drug Discovery Foundation, stated that the results provided encouragement. However, the breakthrough only represents a first step in treating the disease.
尽管如此,投资者需要谨慎行事,不要过多地参与上述生物技术股。阿尔茨海默氏症药物发现基金会首席科学官霍华德·菲利特博士表示,研究结果令人鼓舞。但是,这一突破只是治疗该疾病的第一步。
"Amyloid-clearing drugs will provide an incremental benefit at best and there is still a pressing need for the next generation of drugs focused on other targets based on our knowledge of the biology of aging," he said in an emailed statement to Investor's Business Daily. "We are optimistic about the future as many of these drugs are in development."
他在一份电子邮件声明中说:“清除淀粉样蛋白的药物充其量只能提供增量益处,根据我们对衰老生物学的了解,仍然迫切需要将重点放在其他靶标上的下一代药物。” 《投资者商业日报》。“我们对未来持乐观态度,因为这些药物中有许多正在开发中。”
Still, with the benchmark S&P 500 index down about 8% in the trailing month, Wall Street needed some good news. Investors got it in the form of Alzheimer's-associated biotech stocks.
不过,有了基准 标准普尔 500 该指数在过去一个月中下跌了约8%,华尔街需要一些好消息。投资者以与阿尔茨海默氏症相关的生物技术股票的形式获得。
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
出版之日,Josh Enomoto 没有(直接或间接)持有本文所述证券的任何头寸。本文中表达的观点是作者的观点,受InvestorPlace.com的约束出版指南。
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
乔什·埃诺莫托曾是索尼电子的高级业务分析师,曾帮助促成与财富全球500强公司的重大合同。在过去的几年中,他为投资市场以及包括法律、建筑管理和医疗保健在内的其他各种行业提供了独特的关键见解。
The post Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results appeared first on InvestorPlace.
《生物技术股LLY,ESALY Gain on biogen的阳性试验结果》一文首次出现在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧